首页 > 最新文献

Frontiers in Cardiovascular Medicine最新文献

英文 中文
Association of the geriatric nutritional risk index with poor outcomes in patients with coronary revascularization: a cohort study. 老年营养风险指数与冠状动脉血管重建术患者不良预后的关系:一项队列研究
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-24 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1442957
Beili Xie, Yue Shi, Mingwang Liu, Zhidie Jin, Wei Wen, Yuxin Yan, Mengjie Gao, Lulian Jiang, Lin Yang, Jiangang Liu, Dazhuo Shi, Fuhai Zhao

Background: Poor nutritional status may affect outcomes after coronary revascularization, but the association between nutritional status and outcomes in patients undergoing coronary revascularization has not been fully evaluated. This study was based on the MIMIC-IV database to analyze the impact of baseline nutritional status on poor outcomes in patients with coronary revascularization.

Methods: Patients with coronary revascularization were screened from the MIMIC-IV database. A geriatric nutritional risk index (GNRI) was calculated and used to divide patients into 4 groups: no malnutrition (Q4: ≥96.79), mild malnutrition (Q3: 90.85-96.78), moderate malnutrition (Q2: 86.37-90.84), and severe malnutrition (Q1: 86.37). The primary outcome measure was 28-day mortality, and the secondary outcome measures were AKI and length of hospital stay. Cox proportional hazards model, Kaplan-Meier survival analysis, restricted cubic spline (RCS), and multiple linear regression model were used for statistical analysis, respectively, to ensure the robustness of study results.

Results: A total of 1,168 patients with coronary revascularization were included. The GNRI demonstrated a significant association with 28-day mortality in patients undergoing coronary revascularization. As a continuous variable, the GNRI exhibited a notable inverse correlation with mortality across unadjusted, partially adjusted, and fully adjusted Cox regression models [hazard ratios (HRs): 0.93, 0.94, 0.96, respectively; all P < 0.001]. When considered as a categorical variable, a low GNRI (first quartile, Q1) was significantly associated with elevated mortality risks (HRs: 2.64, 2.30, 1.82 in the unadjusted, partially adjusted, and fully adjusted models, respectively; all P < 0.05). Subgroup analysis revealed a more pronounced association in patients under 65 years of age (P for interaction = 0.014). Furthermore, reduced GNRI levels were also associated with an increased incidence of AKI and extended hospital lengths of stay.

Conclusion: GNRI is associated with prognosis in patients with coronary revascularization. Patients with lower GNRI had higher 28-day mortality, greater risk of AKI, and longer hospital stays.

背景:营养状况不良可能影响冠状动脉血管重建术后的预后,但营养状况与冠状动脉血管重建术患者预后之间的关系尚未得到充分评估。本研究基于MIMIC-IV数据库,分析基线营养状况对冠状动脉血运重建术患者不良预后的影响。方法:从MIMIC-IV数据库中筛选冠脉重建术患者。计算老年营养风险指数(GNRI)并将患者分为4组:无营养不良(Q4:≥96.79)、轻度营养不良(Q3: 90.85-96.78)、中度营养不良(Q2: 86.37-90.84)、重度营养不良(Q1: 86.37)。主要结局指标为28天死亡率,次要结局指标为AKI和住院时间。分别采用Cox比例风险模型、Kaplan-Meier生存分析、限制性三次样条(RCS)和多元线性回归模型进行统计分析,以确保研究结果的稳健性。结果:共纳入1168例冠状动脉血管重建术患者。GNRI与冠状动脉血管重建术患者28天死亡率有显著相关性。作为一个连续变量,GNRI在未调整、部分调整和完全调整的Cox回归模型中与死亡率呈显著负相关[风险比(hr)分别为0.93、0.94和0.96;所有P Q1)与死亡率风险升高显著相关(未调整、部分调整和完全调整模型的hr分别为2.64、2.30、1.82;相互作用P = 0.014)。此外,GNRI水平的降低还与AKI发生率的增加和住院时间的延长有关。结论:GNRI与冠状动脉血运重建术患者的预后相关。GNRI较低的患者28天死亡率较高,AKI风险较高,住院时间较长。
{"title":"Association of the geriatric nutritional risk index with poor outcomes in patients with coronary revascularization: a cohort study.","authors":"Beili Xie, Yue Shi, Mingwang Liu, Zhidie Jin, Wei Wen, Yuxin Yan, Mengjie Gao, Lulian Jiang, Lin Yang, Jiangang Liu, Dazhuo Shi, Fuhai Zhao","doi":"10.3389/fcvm.2024.1442957","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1442957","url":null,"abstract":"<p><strong>Background: </strong>Poor nutritional status may affect outcomes after coronary revascularization, but the association between nutritional status and outcomes in patients undergoing coronary revascularization has not been fully evaluated. This study was based on the MIMIC-IV database to analyze the impact of baseline nutritional status on poor outcomes in patients with coronary revascularization.</p><p><strong>Methods: </strong>Patients with coronary revascularization were screened from the MIMIC-IV database. A geriatric nutritional risk index (GNRI) was calculated and used to divide patients into 4 groups: no malnutrition (<i>Q</i>4: ≥96.79), mild malnutrition (<i>Q</i>3: 90.85-96.78), moderate malnutrition (<i>Q</i>2: 86.37-90.84), and severe malnutrition (<i>Q</i>1: 86.37). The primary outcome measure was 28-day mortality, and the secondary outcome measures were AKI and length of hospital stay. Cox proportional hazards model, Kaplan-Meier survival analysis, restricted cubic spline (RCS), and multiple linear regression model were used for statistical analysis, respectively, to ensure the robustness of study results.</p><p><strong>Results: </strong>A total of 1,168 patients with coronary revascularization were included. The GNRI demonstrated a significant association with 28-day mortality in patients undergoing coronary revascularization. As a continuous variable, the GNRI exhibited a notable inverse correlation with mortality across unadjusted, partially adjusted, and fully adjusted Cox regression models [hazard ratios (HRs): 0.93, 0.94, 0.96, respectively; all <i>P</i> < 0.001]. When considered as a categorical variable, a low GNRI (first quartile, <i>Q</i>1) was significantly associated with elevated mortality risks (HRs: 2.64, 2.30, 1.82 in the unadjusted, partially adjusted, and fully adjusted models, respectively; all <i>P</i> < 0.05). Subgroup analysis revealed a more pronounced association in patients under 65 years of age (<i>P</i> for interaction = 0.014). Furthermore, reduced GNRI levels were also associated with an increased incidence of AKI and extended hospital lengths of stay.</p><p><strong>Conclusion: </strong>GNRI is associated with prognosis in patients with coronary revascularization. Patients with lower GNRI had higher 28-day mortality, greater risk of AKI, and longer hospital stays.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1442957"},"PeriodicalIF":2.8,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703724/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Behavioral and biomedical factors associated with lifestyle modification practices among diagnosed hypertensive patients in pastoral health facilities of southern Ethiopia. 埃塞俄比亚南部牧民卫生机构中诊断为高血压的患者中与生活方式改变做法相关的行为和生物医学因素。
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-24 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1450263
Tagese Yakob, Begidu Yakob, Mesfin Menza Jaldo, Desalegn Dawit, Chernet Elias, Eskinder Israel, Awoke Abraham

Background: More than 23 million deaths and 36.5% of disability-adjusted life-years are the result of the direct effects of unhealthy behavior alone. Daily behaviors have strong implications for health outcomes and quality of life. The aim of this study is to determine the behavioral and biomedical factors associated with lifestyle modification practices among diagnosed hypertensive patients in pastoral health facilities of southern Ethiopia.

Methods: A facility-based cross-sectional study was conducted among 453 diagnosed hypertensive adult patients in pastoral health of southern Ethiopia from June 1/2023 to July 30/2023. The study population was randomly selected from among patients diagnosed with hypertension that was followed up during the study period using a systematic random sampling technique. The data were entered into Epi-Data-4.6.0.2 and exported to SATAT version 14 for analysis. A binary logistic regression model was fitted to determine independent predictors of lifestyle modification practices among hypertensive patients. An adjusted odds ratio with a 95% confidence interval was used to declare a state of significance.

Results: Out of 453 potential participants approached, 433 agreed to successfully participate in the study, for a response rate of 95.6%. Of the total participants, 56.1% (95% CI, 51.38-60.74) of the patients practiced the recommended lifestyle modifications. Alcohol consumption (AOR = 0.64, 95% CI: 0.42-0.96), ever-practiced reducing salt intake (AOR = 2.48, 95% CI: 1.57-3.93), and low-density lipoprotein cholesterol levels in the blood (>160 mg/dl) (AOR = 3.3, 95% CI: 1.72-6.34) were independently associated with lifestyle modifications in patients with hypertension.

Conclusion: This study revealed that the prevalence of lifestyle modification practices (LMP) was low among hypertensive patients. Lifestyle modification is not one-stop practical, but continuous proper awareness creation, counseling, and health education and health promotion are needed to scale up healthy behavior in patients with hypertension to create a good lifestyle.

背景:超过2300万例死亡和36.5%的残疾调整生命年仅是不健康行为直接影响的结果。日常行为对健康结果和生活质量有很大影响。本研究的目的是确定埃塞俄比亚南部牧民卫生机构中诊断为高血压的患者中与生活方式改变实践相关的行为和生物医学因素。方法:对2023年6月1日至2023年7月30日在埃塞俄比亚南部牧区卫生部门诊断为高血压的453名成人患者进行了基于设施的横断面研究。研究人群从诊断为高血压的患者中随机选择,并在研究期间采用系统随机抽样技术进行随访。将数据输入Epi-Data-4.6.0.2并导出到SATAT版本14进行分析。拟合二元logistic回归模型以确定高血压患者生活方式改变的独立预测因素。采用95%置信区间的调整优势比来宣布显著性状态。结果:在接触的453名潜在参与者中,433名同意成功参与研究,响应率为95.6%。在所有参与者中,56.1% (95% CI, 51.38-60.74)的患者遵循了推荐的生活方式改变。饮酒(AOR = 0.64, 95% CI: 0.42-0.96)、经常减少盐摄入量(AOR = 2.48, 95% CI: 1.57-3.93)和血液中低密度脂蛋白胆固醇水平(>160 mg/dl) (AOR = 3.3, 95% CI: 1.72-6.34)与高血压患者的生活方式改变独立相关。结论:本研究显示高血压患者生活方式改变的患病率较低。生活方式的改变不是一站式的实践,而是需要持续的适当的意识创造、咨询、健康教育和健康促进,以扩大高血压患者的健康行为,创造良好的生活方式。
{"title":"Behavioral and biomedical factors associated with lifestyle modification practices among diagnosed hypertensive patients in pastoral health facilities of southern Ethiopia.","authors":"Tagese Yakob, Begidu Yakob, Mesfin Menza Jaldo, Desalegn Dawit, Chernet Elias, Eskinder Israel, Awoke Abraham","doi":"10.3389/fcvm.2024.1450263","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1450263","url":null,"abstract":"<p><strong>Background: </strong>More than 23 million deaths and 36.5% of disability-adjusted life-years are the result of the direct effects of unhealthy behavior alone. Daily behaviors have strong implications for health outcomes and quality of life. The aim of this study is to determine the behavioral and biomedical factors associated with lifestyle modification practices among diagnosed hypertensive patients in pastoral health facilities of southern Ethiopia.</p><p><strong>Methods: </strong>A facility-based cross-sectional study was conducted among 453 diagnosed hypertensive adult patients in pastoral health of southern Ethiopia from June 1/2023 to July 30/2023. The study population was randomly selected from among patients diagnosed with hypertension that was followed up during the study period using a systematic random sampling technique. The data were entered into Epi-Data-4.6.0.2 and exported to SATAT version 14 for analysis. A binary logistic regression model was fitted to determine independent predictors of lifestyle modification practices among hypertensive patients. An adjusted odds ratio with a 95% confidence interval was used to declare a state of significance.</p><p><strong>Results: </strong>Out of 453 potential participants approached, 433 agreed to successfully participate in the study, for a response rate of 95.6%. Of the total participants, 56.1% (95% CI, 51.38-60.74) of the patients practiced the recommended lifestyle modifications. Alcohol consumption (AOR = 0.64, 95% CI: 0.42-0.96), ever-practiced reducing salt intake (AOR = 2.48, 95% CI: 1.57-3.93), and low-density lipoprotein cholesterol levels in the blood (>160 mg/dl) (AOR = 3.3, 95% CI: 1.72-6.34) were independently associated with lifestyle modifications in patients with hypertension.</p><p><strong>Conclusion: </strong>This study revealed that the prevalence of lifestyle modification practices (LMP) was low among hypertensive patients. Lifestyle modification is not one-stop practical, but continuous proper awareness creation, counseling, and health education and health promotion are needed to scale up healthy behavior in patients with hypertension to create a good lifestyle.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1450263"},"PeriodicalIF":2.8,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703905/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946758","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Malignant hypertension: current challenges, prevention strategies, and future perspectives. 恶性高血压:当前的挑战、预防策略和未来展望。
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-24 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1409212
Abate Wondesen Tsige, Siraye Genzeb Ayele

Introduction: Based on office blood pressure (BP) values, hypertension is categorized into three stages: stage 1 (140-159/90-99 mmHg), stage 2 (160-179/100-109 mmHg), and stage 3 (≥180/≥110 mmHg). Malignant hypertension (MHT) is characterized by extreme BP elevation (systolic blood pressure above 200 mmHg and diastolic blood pressure above 130 mmHg) and acute microvascular damage affecting various organs, particularly the retinas, brain, and kidneys.

Objectives: The pathogenesis, predisposing variables, therapy, and preventive strategies for MHT were examined in this review.

Conclusions and recommendations: Malignant hypertension requires prompt and efficient treatment because it is the most severe kind of hypertension that affects target organs. At the same time, there are a number of alternatives available for treating MHT. The International Society of Hypertension 2020 and European Society of Cardiology/European Society of Hypertension 2018 recommendations suggest using labetalol and nicardipine as the first-line choice, with urapidil and nitroprusside serving as alternative medications. Elevated risk of MHT has been linked to many socio-demographic and genetic factors.

简介:根据办公室血压(BP)值,高血压分为三个阶段:1期(140-159/90-99 mmHg), 2期(160-179/100-109 mmHg)和3期(≥180/≥110 mmHg)。恶性高血压(MHT)的特征是极度血压升高(收缩压超过200 mmHg,舒张压超过130 mmHg)和急性微血管损伤,影响各器官,特别是视网膜、脑和肾脏。目的:本文综述MHT的发病机制、易感因素、治疗和预防策略。结论和建议:恶性高血压是影响靶器官的最严重的高血压,需要及时有效的治疗。与此同时,有许多可用于治疗MHT的替代方法。2020年国际高血压学会和2018年欧洲心脏病学会/欧洲高血压学会建议使用拉贝他洛尔和尼卡地平作为一线选择,乌拉地尔和硝普塞作为替代药物。MHT风险升高与许多社会人口和遗传因素有关。
{"title":"Malignant hypertension: current challenges, prevention strategies, and future perspectives.","authors":"Abate Wondesen Tsige, Siraye Genzeb Ayele","doi":"10.3389/fcvm.2024.1409212","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1409212","url":null,"abstract":"<p><strong>Introduction: </strong>Based on office blood pressure (BP) values, hypertension is categorized into three stages: stage 1 (140-159/90-99 mmHg), stage 2 (160-179/100-109 mmHg), and stage 3 (≥180/≥110 mmHg). Malignant hypertension (MHT) is characterized by extreme BP elevation (systolic blood pressure above 200 mmHg and diastolic blood pressure above 130 mmHg) and acute microvascular damage affecting various organs, particularly the retinas, brain, and kidneys.</p><p><strong>Objectives: </strong>The pathogenesis, predisposing variables, therapy, and preventive strategies for MHT were examined in this review.</p><p><strong>Conclusions and recommendations: </strong>Malignant hypertension requires prompt and efficient treatment because it is the most severe kind of hypertension that affects target organs. At the same time, there are a number of alternatives available for treating MHT. The International Society of Hypertension 2020 and European Society of Cardiology/European Society of Hypertension 2018 recommendations suggest using labetalol and nicardipine as the first-line choice, with urapidil and nitroprusside serving as alternative medications. Elevated risk of MHT has been linked to many socio-demographic and genetic factors.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1409212"},"PeriodicalIF":2.8,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703975/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947242","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardiopulmonary exercise response at high altitude in patients with congenital heart disease: a systematic review and meta-analysis. 先天性心脏病患者在高海拔地区的心肺运动反应:系统回顾和荟萃分析
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-24 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1454680
Marco Vecchiato, Federica Duregon, Nicola Borasio, Sara Faggian, Veronica Bassanello, Andrea Aghi, Stefano Palermi, Gino Degano, Francesca Battista, Andrea Ermolao, Daniel Neunhaeuserer

Background: An increasing number of patients with congenital heart disease (CHD) engage in physical activities and may exercise at high altitudes (HA). The physiological adaptations required at HA and their implications on individuals with CHD, especially during exercise, remain underexplored. This systematic review aims to investigate cardiopulmonary exercise responses to short-term HA exposure in individuals with CHD.

Methods: A literature search was performed across PubMed, Cochrane Library, Scopus, Embase, and SPORTDiscus. The search focused on studies comparing patients with CHD to healthy controls, specifically assessing cardiorespiratory responses during cardiopulmonary exercise testing at HA (≥2,500 m) and low altitude (LA). A meta-analysis of the differences in the main cardiorespiratory adaptations during exercise from LA to HA was performed, comparing patients with CHD and controls.

Results: Of the initial 4,500 articles, four studies met the inclusion criteria, encompassing 150 participants (74 with CHD and 76 controls). Almost all the patients with CHD had lower cardiorespiratory fitness and efficiency both at LA and HA compared to the controls. Nevertheless, the patients with CHD showed a smaller decrease in peak workload [10.61 W (95% CI: 2.33-18.88)] and peak saturation [1.22% (95% CI: 0.14-2.30)] between LA and HA compared to the controls. No participants presented exercise-induced symptoms.

Conclusion: Short-term exposure to HA appears to be relatively well-tolerated by individuals with low-risk CHD, without a significantly different impact on cardiorespiratory response compared to healthy controls. Further research should confirm these outcomes and explore the long-term effects of higher altitude exposure as comprehensive recommendations for these patients are lacking.

背景:越来越多的先天性心脏病(CHD)患者参与体育活动,并可能在高海拔地区(HA)进行锻炼。HA所需的生理适应及其对冠心病患者的影响,特别是在运动期间,仍未得到充分研究。本系统综述旨在探讨冠心病患者短期HA暴露对心肺运动的影响。方法:通过PubMed、Cochrane Library、Scopus、Embase和SPORTDiscus进行文献检索。该研究的重点是比较冠心病患者与健康对照者的研究,特别是评估HA(≥2,500 m)和低海拔(LA)心肺运动试验期间的心肺反应。进行了一项荟萃分析,比较冠心病患者和对照组在LA和HA运动期间主要心肺适应的差异。结果:在最初的4500篇文章中,有4篇研究符合纳入标准,包括150名参与者(74名冠心病患者和76名对照组)。与对照组相比,几乎所有冠心病患者在LA和HA时的心肺适能和效率都较低。然而,与对照组相比,冠心病患者在LA和HA之间的峰值负荷[10.61 W (95% CI: 2.33-18.88)]和峰值饱和度[1.22% (95% CI: 0.14-2.30)]的下降幅度较小。没有参与者出现运动引起的症状。结论:低风险冠心病患者短期暴露于HA的耐受性相对较好,与健康对照组相比,对心肺反应没有明显不同的影响。进一步的研究应该证实这些结果,并探索高海拔暴露的长期影响,因为缺乏对这些患者的综合建议。
{"title":"Cardiopulmonary exercise response at high altitude in patients with congenital heart disease: a systematic review and meta-analysis.","authors":"Marco Vecchiato, Federica Duregon, Nicola Borasio, Sara Faggian, Veronica Bassanello, Andrea Aghi, Stefano Palermi, Gino Degano, Francesca Battista, Andrea Ermolao, Daniel Neunhaeuserer","doi":"10.3389/fcvm.2024.1454680","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1454680","url":null,"abstract":"<p><strong>Background: </strong>An increasing number of patients with congenital heart disease (CHD) engage in physical activities and may exercise at high altitudes (HA). The physiological adaptations required at HA and their implications on individuals with CHD, especially during exercise, remain underexplored. This systematic review aims to investigate cardiopulmonary exercise responses to short-term HA exposure in individuals with CHD.</p><p><strong>Methods: </strong>A literature search was performed across PubMed, Cochrane Library, Scopus, Embase, and SPORTDiscus. The search focused on studies comparing patients with CHD to healthy controls, specifically assessing cardiorespiratory responses during cardiopulmonary exercise testing at HA (≥2,500 m) and low altitude (LA). A meta-analysis of the differences in the main cardiorespiratory adaptations during exercise from LA to HA was performed, comparing patients with CHD and controls.</p><p><strong>Results: </strong>Of the initial 4,500 articles, four studies met the inclusion criteria, encompassing 150 participants (74 with CHD and 76 controls). Almost all the patients with CHD had lower cardiorespiratory fitness and efficiency both at LA and HA compared to the controls. Nevertheless, the patients with CHD showed a smaller decrease in peak workload [10.61 W (95% CI: 2.33-18.88)] and peak saturation [1.22% (95% CI: 0.14-2.30)] between LA and HA compared to the controls. No participants presented exercise-induced symptoms.</p><p><strong>Conclusion: </strong>Short-term exposure to HA appears to be relatively well-tolerated by individuals with low-risk CHD, without a significantly different impact on cardiorespiratory response compared to healthy controls. Further research should confirm these outcomes and explore the long-term effects of higher altitude exposure as comprehensive recommendations for these patients are lacking.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1454680"},"PeriodicalIF":2.8,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703806/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142946954","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence and predictors of poor heart failure treatment outcomes in Ethiopia: a systematic review and meta-analysis. 埃塞俄比亚不良心力衰竭治疗结果的患病率和预测因素:系统回顾和荟萃分析。
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-24 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1434265
Firomsa Bekele, Lalise Tafese, Ginenus Fekadu, Geleta Nenko Dube, Dinka Dugassa, Dagim Samuel

Background: Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Various factors can exacerbate disease progression in patients with HF and negatively impact treatment outcomes. This study aims to evaluate the pooled prevalence and contributing factors associated with poor heart failure treatment outcomes in Ethiopia.

Methods: A systematic review and meta-analysis were conducted using five databases: Google Scholar, ScienceDirect, Hinari, PubMed, and Scopus. In total, 12 studies met the eligibility criteria for inclusion in this analysis. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Data extraction was performed using a Microsoft Excel spreadsheet, and statistical analysis was conducted with STATA 14. The Joanna Briggs Institute Meta-analysis of Statistics Assessment and Review Instrument was utilized for quality assessment. Heterogeneity among the studies was evaluated using the I 2 statistic and the Cochrane Q test. Publication bias was assessed using Begg's test, Egger's weighted regression, and funnel plots.

Results: The pooled prevalence of poor HF treatment outcomes was found to be 16.67% [95% confidence interval (CI): 10.67-22.67]. No significant heterogeneity was observed across the included studies (I 2 = 0.0%, p = 0.962). Significant predictors of a poor treatment outcome were smoking cigarettes [adjusted odds ratio (AOR) = 10.74; 95% CI: 3.24-35.63] and medication-related problems (AOR = 3.99; 95% CI: 1.90-8.37).

Conclusion: The prevalence of poor HF treatment outcomes in Ethiopia was found to be high. Smoking cigarettes and medication-related problems are significant predictors of these adverse outcomes. Comprehensive health education and improved clinical pharmacy services are essential for addressing these issues.

Systematic review registration: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023437397, PROSPERO (CRD42023437397).

背景:心力衰竭(HF)是全世界发病率和死亡率的主要原因。各种因素可加剧心衰患者的疾病进展,并对治疗结果产生负面影响。本研究旨在评估埃塞俄比亚心力衰竭治疗结果不佳的综合患病率和相关因素。方法:采用谷歌Scholar、ScienceDirect、Hinari、PubMed和Scopus五个数据库进行系统综述和荟萃分析。总共有12项研究符合纳入本分析的资格标准。该综述遵循了2020年系统评价和荟萃分析指南的首选报告项目。数据提取采用Microsoft Excel电子表格,统计分析采用STATA 14。采用乔安娜布里格斯研究所统计荟萃分析评估和回顾工具进行质量评估。采用i2统计量和Cochrane Q检验评估研究间的异质性。采用Begg检验、Egger加权回归和漏斗图评估发表偏倚。结果:HF治疗结果不良的总发生率为16.67%[95%置信区间(CI): 10.67-22.67]。纳入的研究间无显著异质性(i2 = 0.0%, p = 0.962)。不良治疗结果的显著预测因子是吸烟[校正优势比(AOR) = 10.74;95% CI: 3.24-35.63]和药物相关问题(AOR = 3.99;95% ci: 1.90-8.37)。结论:在埃塞俄比亚,心衰治疗结果不佳的发生率很高。吸烟和药物相关问题是这些不良结果的重要预测因素。全面的健康教育和改善临床药学服务是解决这些问题的关键。系统评价注册:https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023437397, PROSPERO (CRD42023437397)。
{"title":"Prevalence and predictors of poor heart failure treatment outcomes in Ethiopia: a systematic review and meta-analysis.","authors":"Firomsa Bekele, Lalise Tafese, Ginenus Fekadu, Geleta Nenko Dube, Dinka Dugassa, Dagim Samuel","doi":"10.3389/fcvm.2024.1434265","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1434265","url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) is a leading cause of morbidity and mortality worldwide. Various factors can exacerbate disease progression in patients with HF and negatively impact treatment outcomes. This study aims to evaluate the pooled prevalence and contributing factors associated with poor heart failure treatment outcomes in Ethiopia.</p><p><strong>Methods: </strong>A systematic review and meta-analysis were conducted using five databases: Google Scholar, ScienceDirect, Hinari, PubMed, and Scopus. In total, 12 studies met the eligibility criteria for inclusion in this analysis. The review followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses 2020 guidelines. Data extraction was performed using a Microsoft Excel spreadsheet, and statistical analysis was conducted with STATA 14. The Joanna Briggs Institute Meta-analysis of Statistics Assessment and Review Instrument was utilized for quality assessment. Heterogeneity among the studies was evaluated using the <i>I</i> <sup>2</sup> statistic and the Cochrane <i>Q</i> test. Publication bias was assessed using Begg's test, Egger's weighted regression, and funnel plots.</p><p><strong>Results: </strong>The pooled prevalence of poor HF treatment outcomes was found to be 16.67% [95% confidence interval (CI): 10.67-22.67]. No significant heterogeneity was observed across the included studies (<i>I</i> <sup>2</sup> = 0.0%, <i>p</i> = 0.962). Significant predictors of a poor treatment outcome were smoking cigarettes [adjusted odds ratio (AOR) = 10.74; 95% CI: 3.24-35.63] and medication-related problems (AOR = 3.99; 95% CI: 1.90-8.37).</p><p><strong>Conclusion: </strong>The prevalence of poor HF treatment outcomes in Ethiopia was found to be high. Smoking cigarettes and medication-related problems are significant predictors of these adverse outcomes. Comprehensive health education and improved clinical pharmacy services are essential for addressing these issues.</p><p><strong>Systematic review registration: </strong>https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023437397, PROSPERO (CRD42023437397).</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1434265"},"PeriodicalIF":2.8,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703969/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947245","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
VA-ECOM assisted percutaneous mechanical thrombectomy treatment high-risk pulmonary embolism. VA-ECOM辅助经皮机械取栓治疗高危肺栓塞。
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-24 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1457157
Zhenhang Zhou, Yaoyang Zhong, Jianbo Hu, Zhonghua Wu, Liping Zou, Zhihe Deng, Guoshan Bi, Xin Shen, Xianpeng Dai, Zhijia Huang, Guozuo Xiong, Yiming Xu, Liming Deng

Background: Percutaneous mechanical thrombectomy (PMT) is increasingly used in the treatment of intermediate and high-risk acute pulmonary embolism (PE), and the treatment of high-risk PE with the aid of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has also been reported. However, there are few reports of VA-ECOM-assisted PMT in the treatment of high-risk PE. The purpose of this study is to summarize the data of 11 patients with high-risk PE treated with VA-ECMO assisted PMT, and propose feasible treatment methods for such patients.

Methods: This multicenter retrospective study included patients with acute high-risk PE who were treated with VA-ECMO-assisted PMT from January 2021 to June 2024. The analysis focused on the right/left ventricle ratio, biomarkers, and pulmonary artery pressure before and after the VA-ECMO-assisted PMT treatment.

Results: All 11 high-risk PE patients suffered cardiac arrest before treatment, computered tomograhy pulmonary angiography (CTPA) confirmed the diagnosis of PE, and all patients received VA-ECMO-assisted PMT therapy. The median age of the 11 patients was 54 years (range 18-72), the median duration of ECMO was 4.48 days (range 1.04-18.02), and the mean hospitalization time was 21 days (range 14-112). All patients received percutaneous thrombectomy, achieving a 100% technical success rate. The mortality rate was 27.3% during the 90-day follow-up. The 12-month mortality rate was 36.4%.

Conclusion: VA-ECMO-assisted PMT technology can rapidly improve pulmonary hemodynamics while maintaining stable blood flow, thereby reducing in-hospital mortality in high-risk patients with pulmonary embolism complicated by cardiac arrest.

背景:经皮机械取栓术(PMT)越来越多地应用于中、高危急性肺栓塞(PE)的治疗,静脉-动脉体外膜氧合(VA-ECMO)辅助治疗高危肺栓塞也有报道。然而,va - ecom辅助PMT治疗高危PE的报道很少。本研究的目的是总结11例采用VA-ECMO辅助PMT治疗的高危PE患者的资料,并对该类患者提出可行的治疗方法。方法:这项多中心回顾性研究纳入了2021年1月至2024年6月期间接受va - ecmo辅助PMT治疗的急性高危PE患者。分析的重点是va - ecmo辅助PMT治疗前后的右/左心室比率、生物标志物和肺动脉压。结果:11例PE高危患者治疗前均出现心脏骤停,ct肺血管造影(CTPA)均确诊为PE,均接受va - ecmo辅助PMT治疗。11例患者的中位年龄为54岁(范围18-72),ECMO的中位持续时间为4.48天(范围1.04-18.02),平均住院时间为21天(范围14-112)。所有患者均行经皮取栓术,技术成功率100%。90天随访期间死亡率为27.3%。12个月死亡率为36.4%。结论:va - ecmo辅助PMT技术可在保持稳定血流的同时快速改善肺血流动力学,从而降低肺栓塞合并心脏骤停高危患者的住院死亡率。
{"title":"VA-ECOM assisted percutaneous mechanical thrombectomy treatment high-risk pulmonary embolism.","authors":"Zhenhang Zhou, Yaoyang Zhong, Jianbo Hu, Zhonghua Wu, Liping Zou, Zhihe Deng, Guoshan Bi, Xin Shen, Xianpeng Dai, Zhijia Huang, Guozuo Xiong, Yiming Xu, Liming Deng","doi":"10.3389/fcvm.2024.1457157","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1457157","url":null,"abstract":"<p><strong>Background: </strong>Percutaneous mechanical thrombectomy (PMT) is increasingly used in the treatment of intermediate and high-risk acute pulmonary embolism (PE), and the treatment of high-risk PE with the aid of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has also been reported. However, there are few reports of VA-ECOM-assisted PMT in the treatment of high-risk PE. The purpose of this study is to summarize the data of 11 patients with high-risk PE treated with VA-ECMO assisted PMT, and propose feasible treatment methods for such patients.</p><p><strong>Methods: </strong>This multicenter retrospective study included patients with acute high-risk PE who were treated with VA-ECMO-assisted PMT from January 2021 to June 2024. The analysis focused on the right/left ventricle ratio, biomarkers, and pulmonary artery pressure before and after the VA-ECMO-assisted PMT treatment.</p><p><strong>Results: </strong>All 11 high-risk PE patients suffered cardiac arrest before treatment, computered tomograhy pulmonary angiography (CTPA) confirmed the diagnosis of PE, and all patients received VA-ECMO-assisted PMT therapy. The median age of the 11 patients was 54 years (range 18-72), the median duration of ECMO was 4.48 days (range 1.04-18.02), and the mean hospitalization time was 21 days (range 14-112). All patients received percutaneous thrombectomy, achieving a 100% technical success rate. The mortality rate was 27.3% during the 90-day follow-up. The 12-month mortality rate was 36.4%.</p><p><strong>Conclusion: </strong>VA-ECMO-assisted PMT technology can rapidly improve pulmonary hemodynamics while maintaining stable blood flow, thereby reducing in-hospital mortality in high-risk patients with pulmonary embolism complicated by cardiac arrest.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1457157"},"PeriodicalIF":2.8,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11703816/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947163","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association between asthma and cardiovascular disease: evidence from the national health and nutrition examination survey 1999-2018. 哮喘与心血管疾病之间的关系:来自1999-2018年全国健康与营养检查调查的证据
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-20 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1367576
Biao Peng, Wenjing Zhao, Fang Wan, Zhonghai Ji, Runkun Luo, Sheng Wang, Anhua Cao, Zhichao Yang, Da Liu, Changchun Tang, Ping Deng

Background: Cardiovascular disease(CVD) remains a significant global challenge. Asthma, which is characterized by airway hyperresponsiveness and reversible and limited airflow, plays an important role in cardiovascular diseases. This study aimed to investigate the association between asthma and CVD.

Methods: This cross-sectional study included demographic, laboratory, and questionnaire data from the National Health and Nutrition Examination Survey (NHANES) 1999-2018. CVD included stroke, congestive heart failure, coronary heart disease, and angina. Multiple logistic regression models were used to detect the association between asthma and the prevalence of CVD, adjusting for age, gender, race, education level, body mass index, ratio of family income to poverty, smoking exposure, drinking exposure, diabetes history, hypertension history, chronic obstructive pulmonary disease (COPD) history, and chronic kidney disease (CKD) history. A subgroup analysis was performed to investigate the association between asthma and CVD in different populations.

Results: In total, 16,807 participants were included in this study, including 2,446 who reported having asthma. Compared with participants without asthma, the prevalence of stroke in those with asthma was increased by 1.607 times; the prevalence of congestive heart failure was increased by 1.911 times. Asthma significantly increased the prevalence of stroke among participants aged 18-44 years old, with a BMI 18.50-29.99 kg/m2, with low education levels, and with a PIR < 1.00. Asthma also increased the prevalence of angina in females, non-Hispanic Blacks, participants aged 45-59 years old, with a BMI ≥ 30.00 kg/m2, and with a PIR < 1.00. The prevalence of congestive heart failure was positively associated with asthma in non-Hispanic Whites or Blacks, participants aged ≥45 years old, with a BMI 25.00-29.99 kg/m2, with a PIR < 1.00, and with a low or middle education level.

Conclusion: Asthma significantly increases the prevalence of stroke, congestive heart failure. Patients with asthma should be monitored for CVD, including stroke and congestive heart failure.

背景:心血管疾病(CVD)仍然是一个重大的全球性挑战。哮喘以气道高反应性和可逆性气流受限为特征,在心血管疾病中起重要作用。本研究旨在探讨哮喘与心血管疾病之间的关系。方法:本横断面研究包括1999-2018年国家健康与营养检查调查(NHANES)的人口统计、实验室和问卷数据。CVD包括中风、充血性心力衰竭、冠心病和心绞痛。在调整年龄、性别、种族、受教育程度、体重指数、家庭收入与贫困比例、吸烟暴露、饮酒暴露、糖尿病史、高血压史、慢性阻塞性肺疾病(COPD)史和慢性肾脏疾病(CKD)史等因素后,采用多元logistic回归模型检测哮喘与CVD患病率之间的关系。进行亚组分析以调查不同人群中哮喘和心血管疾病之间的关系。结果:共有16807名参与者参与了这项研究,其中2446人报告患有哮喘。与无哮喘的受试者相比,哮喘患者的卒中患病率增加了1.607倍;充血性心力衰竭患病率增加1.911倍。哮喘显著增加了18-44岁、BMI为18.50-29.99 kg/m2、受教育程度低、PIR为2、PIR为2、PIR为1的参与者的中风患病率。结论:哮喘显著增加了中风、充血性心力衰竭的患病率。哮喘患者应监测心血管疾病,包括中风和充血性心力衰竭。
{"title":"Association between asthma and cardiovascular disease: evidence from the national health and nutrition examination survey 1999-2018.","authors":"Biao Peng, Wenjing Zhao, Fang Wan, Zhonghai Ji, Runkun Luo, Sheng Wang, Anhua Cao, Zhichao Yang, Da Liu, Changchun Tang, Ping Deng","doi":"10.3389/fcvm.2024.1367576","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1367576","url":null,"abstract":"<p><strong>Background: </strong>Cardiovascular disease(CVD) remains a significant global challenge. Asthma, which is characterized by airway hyperresponsiveness and reversible and limited airflow, plays an important role in cardiovascular diseases. This study aimed to investigate the association between asthma and CVD.</p><p><strong>Methods: </strong>This cross-sectional study included demographic, laboratory, and questionnaire data from the National Health and Nutrition Examination Survey (NHANES) 1999-2018. CVD included stroke, congestive heart failure, coronary heart disease, and angina. Multiple logistic regression models were used to detect the association between asthma and the prevalence of CVD, adjusting for age, gender, race, education level, body mass index, ratio of family income to poverty, smoking exposure, drinking exposure, diabetes history, hypertension history, chronic obstructive pulmonary disease (COPD) history, and chronic kidney disease (CKD) history. A subgroup analysis was performed to investigate the association between asthma and CVD in different populations.</p><p><strong>Results: </strong>In total, 16,807 participants were included in this study, including 2,446 who reported having asthma. Compared with participants without asthma, the prevalence of stroke in those with asthma was increased by 1.607 times; the prevalence of congestive heart failure was increased by 1.911 times. Asthma significantly increased the prevalence of stroke among participants aged 18-44 years old, with a BMI 18.50-29.99 kg/m<sup>2</sup>, with low education levels, and with a PIR < 1.00. Asthma also increased the prevalence of angina in females, non-Hispanic Blacks, participants aged 45-59 years old, with a BMI ≥ 30.00 kg/m<sup>2</sup>, and with a PIR < 1.00. The prevalence of congestive heart failure was positively associated with asthma in non-Hispanic Whites or Blacks, participants aged ≥45 years old, with a BMI 25.00-29.99 kg/m<sup>2</sup>, with a PIR < 1.00, and with a low or middle education level.</p><p><strong>Conclusion: </strong>Asthma significantly increases the prevalence of stroke, congestive heart failure. Patients with asthma should be monitored for CVD, including stroke and congestive heart failure.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1367576"},"PeriodicalIF":2.8,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695316/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931134","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The association between cardiovascular health and obstructive sleep apnea symptoms: findings from NHANES. 心血管健康与阻塞性睡眠呼吸暂停症状之间的关系:来自NHANES的研究结果
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-20 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1466752
Qian Guo, Dong Dong, Qiang Zhou, Shuman Huang, Xinjie Qiao, Zihan Dang, Xiaowu Wang, Yulin Zhao

Objective: To investigate the association between cardiovascular health (CVH) and obstructive sleep apnea (OSA) within the U.S. population.

Methods: This study enrolled 12,540 participants aged 20 years and older from the 2007-2008 and 2015-2018 cycles of the National Health and Nutrition Examination Surveys (NHANES). Weighted univariate and multivariate logistic regression were utilized to examine the relationship between CVH and OSA symptoms. Life's Essential 8 (LE 8) metrics was employed to evaluate the CVH status of participants. Identification of OSA symptoms was determined based on a sleep questionnaire. They include (1) how often you snore; (2) how often you snort/stop breathing; or (3) how often you feel overly sleepy during day. Individuals who answered that they snore 3 or more per week; snort/stop breathing 3 or more per week and feel overly sleepy during day 16-30 times per month were classified as having OSA symptoms.

Results: Significant inverse associations were observed between LE8 scores and symptoms of OSA after adjusting for covariates. The 95% CI was 0.750 (0.630,0.893) for the moderate CVH group and 0.573 (0.454,0.723) for the high CVH group. Subgroup analyses, stratified by age and gender, highlighted a significant interaction between LE8 scores and OSA symptoms with age (P < 0.0001). Participants under 60 years old in the high CVH group exhibited a reduced likelihood OSA symptoms (OR: 0.470; 95% CI: 0.345,0.641). Restricted cubic splines (RCS) in a multivariate regression analysis showed a non-linear relationship between LE8 score and OSA. Our finding demonstrates a substantial decrease in OSA symptom prevalence with increased LE 8 scores.

Conclusion: The results demonstrate a strong inverse correlation between LE8 scores and OSA symptoms. Participants with higher LE8 scores showed a reduced likelihood of experiencing OSA symptoms.

目的:调查美国人群中心血管健康(CVH)与阻塞性睡眠呼吸暂停(OSA)之间的关系。方法:本研究招募了来自2007-2008年和2015-2018年国家健康与营养检查调查(NHANES)周期的12540名20岁及以上的参与者。采用加权单因素和多因素logistic回归分析CVH与OSA症状的关系。采用生命基本8 (LE 8)指标评估参与者的CVH状态。根据睡眠问卷确定OSA症状的识别。它们包括:(1)你打鼾的频率;(2)你多久吸一次鼻息/停止呼吸一次;或者(3)你在白天多久感到过度困倦。回答每周打鼾3次或更多的人;每周喷鼻或停止呼吸3次或以上,每月16-30次白天感到过度困倦,被归类为阻塞性睡眠呼吸暂停症状。结果:调整协变量后,LE8评分与OSA症状呈显著负相关。中度CVH组的95% CI为0.750(0.630,0.893),高CVH组的95% CI为0.573(0.454,0.723)。按年龄和性别分层的亚组分析显示,LE8评分与OSA症状随年龄的增加存在显著的相互作用(P)。结论:LE8评分与OSA症状呈强负相关。LE8得分较高的参与者出现OSA症状的可能性较低。
{"title":"The association between cardiovascular health and obstructive sleep apnea symptoms: findings from NHANES.","authors":"Qian Guo, Dong Dong, Qiang Zhou, Shuman Huang, Xinjie Qiao, Zihan Dang, Xiaowu Wang, Yulin Zhao","doi":"10.3389/fcvm.2024.1466752","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1466752","url":null,"abstract":"<p><strong>Objective: </strong>To investigate the association between cardiovascular health (CVH) and obstructive sleep apnea (OSA) within the U.S. population.</p><p><strong>Methods: </strong>This study enrolled 12,540 participants aged 20 years and older from the 2007-2008 and 2015-2018 cycles of the National Health and Nutrition Examination Surveys (NHANES). Weighted univariate and multivariate logistic regression were utilized to examine the relationship between CVH and OSA symptoms. Life's Essential 8 (LE 8) metrics was employed to evaluate the CVH status of participants. Identification of OSA symptoms was determined based on a sleep questionnaire. They include (1) how often you snore; (2) how often you snort/stop breathing; or (3) how often you feel overly sleepy during day. Individuals who answered that they snore 3 or more per week; snort/stop breathing 3 or more per week and feel overly sleepy during day 16-30 times per month were classified as having OSA symptoms.</p><p><strong>Results: </strong>Significant inverse associations were observed between LE8 scores and symptoms of OSA after adjusting for covariates. The 95% CI was 0.750 (0.630,0.893) for the moderate CVH group and 0.573 (0.454,0.723) for the high CVH group. Subgroup analyses, stratified by age and gender, highlighted a significant interaction between LE8 scores and OSA symptoms with age (<i>P</i> < 0.0001). Participants under 60 years old in the high CVH group exhibited a reduced likelihood OSA symptoms (OR: 0.470; 95% CI: 0.345,0.641). Restricted cubic splines (RCS) in a multivariate regression analysis showed a non-linear relationship between LE8 score and OSA. Our finding demonstrates a substantial decrease in OSA symptom prevalence with increased LE 8 scores.</p><p><strong>Conclusion: </strong>The results demonstrate a strong inverse correlation between LE8 scores and OSA symptoms. Participants with higher LE8 scores showed a reduced likelihood of experiencing OSA symptoms.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1466752"},"PeriodicalIF":2.8,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695300/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931141","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Editorial: The non-neuronal cholinergic system in the cardiovascular system: its influence on the heart, vasculature, and the central nervous system. 社论:心血管系统中的非神经元胆碱能系统:其对心脏、脉管系统和中枢神经系统的影响。
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-20 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1523385
Yoshihiko Kakinuma, Takashi Sonobe, Rajesh Katare
{"title":"Editorial: The non-neuronal cholinergic system in the cardiovascular system: its influence on the heart, vasculature, and the central nervous system.","authors":"Yoshihiko Kakinuma, Takashi Sonobe, Rajesh Katare","doi":"10.3389/fcvm.2024.1523385","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1523385","url":null,"abstract":"","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1523385"},"PeriodicalIF":2.8,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695400/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931138","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of the derived inflammatory marker SIRI in postmenopausal women with coronary artery disease. 衍生炎症标志物SIRI在绝经后冠心病妇女中的预后价值
IF 2.8 3区 医学 Q2 CARDIAC & CARDIOVASCULAR SYSTEMS Pub Date : 2024-12-20 eCollection Date: 2024-01-01 DOI: 10.3389/fcvm.2024.1418781
Pengli Yang, Rui Xue, Yuhang Wei, Chenxi Cao, Songcheng Yu, Shanling Peng, Wenjing Zhang, Yunzhe Wang, Yingying Zheng, Gangqiong Liu

Objective: The aim of this study was to explore the predictive value of the Systemic Inflammatory Response Index (SIRI) for the prognosis of older postmenopausal women with coronary artery disease (CAD).

Patients and methods: This retrospective cohort study included 617 postmenopausal female patients aged 50 years or older with a CAD diagnosis confirmed by coronary angiography seen at the First Affiliated Hospital of Zhengzhou University from January 2019 to December 2020. Patients were divided into three groups based on SIRI tertiles. Primary endpoints were all-cause mortality (ACM) and cardiac mortality (CM), and secondary endpoints were major adverse cardiovascular events (MACEs) and major adverse cardiovascular and cerebrovascular events (MACCEs).

Results: The frequencies of all adverse outcomes were greater in the high level (third tertile) SIRI group than in the low level (first tertile) SIRI group. Multivariable regression analysis showed that compared to the low level SIRI group, the high level SIRI group had a 1.581-fold greater risk of ACM [hazard ratio (HR) = 2.581, 95% confidence interval (CI): 1.045-6.373, p = 0.040) and a 1.798-fold greater risk of CM (HR = 2.798, 95% CI: 0.972-8.060, p = 0.057). In addition, the risks of MACEs and MACCEs were 62.3% (HR = 1.623, 95% CI: 1.123-2.346, p = 0.01) and 55.8% (HR = 1.558, 95% CI: 1.100-2.207, p = 0.012) greater in the high level SIRI group compared with the low level SIRI group. Kaplan-Meier survival analyses confirmed that the high SIRI level was associated with increased risks of ACM (p = 0.001), CM (p = 0.005), MACEs (p = 0.003), and MACCEs (p = 0.005).

Conclusion: This retrospective study demonstrates that the novel derived inflammatory index SIRI can effectively predict the risk of multiple adverse outcomes in postmenopausal women with CAD.

目的:探讨系统性炎症反应指数(SIRI)对老年绝经后冠心病(CAD)妇女预后的预测价值。患者和方法:本回顾性队列研究纳入2019年1月至2020年12月在郑州大学第一附属医院就诊的经冠状动脉造影确诊冠心病的绝经后女性患者617例,年龄在50岁及以上。根据SIRI评分将患者分为三组。主要终点是全因死亡率(ACM)和心脏死亡率(CM),次要终点是主要不良心血管事件(mace)和主要不良心脑血管事件(MACCEs)。结果:高水平(第三十分位)SIRI组的所有不良后果发生率均高于低水平(第一十分位)SIRI组。多变量回归分析显示,与低水平SIRI组相比,高水平SIRI组发生ACM的风险增加了1.581倍[风险比(HR) = 2.581, 95%可信区间(CI): 1.045 ~ 6.373, p = 0.040],发生CM的风险增加了1.798倍(HR = 2.798, 95% CI: 0.972 ~ 8.060, p = 0.057)。此外,高水平SIRI组与低水平SIRI组相比,mace和MACCEs的风险分别为62.3% (HR = 1.623, 95% CI: 1.123-2.346, p = 0.01)和55.8% (HR = 1.558, 95% CI: 1.100-2.207, p = 0.012)。Kaplan-Meier生存分析证实,高SIRI水平与ACM (p = 0.001)、CM (p = 0.005)、mace (p = 0.003)和MACCEs (p = 0.005)的风险增加相关。结论:本回顾性研究表明,新型衍生炎症指数SIRI可有效预测绝经后CAD患者多种不良结局的风险。
{"title":"Prognostic value of the derived inflammatory marker SIRI in postmenopausal women with coronary artery disease.","authors":"Pengli Yang, Rui Xue, Yuhang Wei, Chenxi Cao, Songcheng Yu, Shanling Peng, Wenjing Zhang, Yunzhe Wang, Yingying Zheng, Gangqiong Liu","doi":"10.3389/fcvm.2024.1418781","DOIUrl":"https://doi.org/10.3389/fcvm.2024.1418781","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to explore the predictive value of the Systemic Inflammatory Response Index (SIRI) for the prognosis of older postmenopausal women with coronary artery disease (CAD).</p><p><strong>Patients and methods: </strong>This retrospective cohort study included 617 postmenopausal female patients aged 50 years or older with a CAD diagnosis confirmed by coronary angiography seen at the First Affiliated Hospital of Zhengzhou University from January 2019 to December 2020. Patients were divided into three groups based on SIRI tertiles. Primary endpoints were all-cause mortality (ACM) and cardiac mortality (CM), and secondary endpoints were major adverse cardiovascular events (MACEs) and major adverse cardiovascular and cerebrovascular events (MACCEs).</p><p><strong>Results: </strong>The frequencies of all adverse outcomes were greater in the high level (third tertile) SIRI group than in the low level (first tertile) SIRI group. Multivariable regression analysis showed that compared to the low level SIRI group, the high level SIRI group had a 1.581-fold greater risk of ACM [hazard ratio (HR) = 2.581, 95% confidence interval (CI): 1.045-6.373, <i>p</i> = 0.040) and a 1.798-fold greater risk of CM (HR = 2.798, 95% CI: 0.972-8.060, <i>p</i> = 0.057). In addition, the risks of MACEs and MACCEs were 62.3% (HR = 1.623, 95% CI: 1.123-2.346, <i>p</i> = 0.01) and 55.8% (HR = 1.558, 95% CI: 1.100-2.207, <i>p</i> = 0.012) greater in the high level SIRI group compared with the low level SIRI group. Kaplan-Meier survival analyses confirmed that the high SIRI level was associated with increased risks of ACM (<i>p</i> = 0.001), CM (<i>p</i> = 0.005), MACEs (<i>p</i> = 0.003), and MACCEs (<i>p</i> = 0.005).</p><p><strong>Conclusion: </strong>This retrospective study demonstrates that the novel derived inflammatory index SIRI can effectively predict the risk of multiple adverse outcomes in postmenopausal women with CAD.</p>","PeriodicalId":12414,"journal":{"name":"Frontiers in Cardiovascular Medicine","volume":"11 ","pages":"1418781"},"PeriodicalIF":2.8,"publicationDate":"2024-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11695340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142931139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Frontiers in Cardiovascular Medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1